Osteosarcoma in the first decade of life
Corresponding Author
Rajaram Nagarajan MD
Department of Pediatrics, Division of Epidemiology and Clinical Research, University of Minnesota, Minneapolis, Minnesota
Pediatric Hematology/Oncology/Blood and Marrow Transplant, University of Minnesota, Mayo Mail Code 484, 420 Delaware St. SE, Minneapolis, MN 55455.Search for more papers by this authorBrenda J. Weigel MD
Department of Pediatrics, Division of Hematology/Oncology/Blood and Marrow Transplant, University of Minnesota, Minneapolis, Minnesota
Search for more papers by this authorRoby C. Thompson MD
Department of Orthopedic Surgery, University of Minnesota, Minneapolis, Minnesota
Search for more papers by this authorJohn P. Perentesis MD
Division of Hematology/Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Search for more papers by this authorCorresponding Author
Rajaram Nagarajan MD
Department of Pediatrics, Division of Epidemiology and Clinical Research, University of Minnesota, Minneapolis, Minnesota
Pediatric Hematology/Oncology/Blood and Marrow Transplant, University of Minnesota, Mayo Mail Code 484, 420 Delaware St. SE, Minneapolis, MN 55455.Search for more papers by this authorBrenda J. Weigel MD
Department of Pediatrics, Division of Hematology/Oncology/Blood and Marrow Transplant, University of Minnesota, Minneapolis, Minnesota
Search for more papers by this authorRoby C. Thompson MD
Department of Orthopedic Surgery, University of Minnesota, Minneapolis, Minnesota
Search for more papers by this authorJohn P. Perentesis MD
Division of Hematology/Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Search for more papers by this author
REFERENCES
- 1 Meyers P, Heller G, Healey J, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: The Memorial Sloan–Kettering experience. J Clin Oncol 1992; 10: 5–15.
- 2
Rosen G,
Marcove R,
Caparros B, et al.
Primary osteogenic sarcoma: The rationale for preoperative chemotherapy and delayed surgery.
Cancer
1979;
43:
2163–2177.
10.1002/1097-0142(197906)43:6<2163::AID-CNCR2820430602>3.0.CO;2-S CAS PubMed Web of Science® Google Scholar
- 3 Spanier S, Shuster J, Vander Griend R. The effect of local extent of the tumor on prognosis in osteosarcoma. J Bone Joint Surg Am 1990; 72: 643–653.
- 4 Winkler K, Beron G, Kotz R, et al. Neoadjuvant chemotherapy for osteogenic sarcoma: Results of a cooperative German/Austrian study. J Clin Oncol 1984; 2: 617–624.
- 5
Bentzen S,
Poulsen H,
Kaae S, et al.
Prognostic factors in osteosarcoma: A regression analysis.
Cancer
1988;
62:
194–202.
10.1002/1097-0142(19880701)62:1<194::AID-CNCR2820620129>3.0.CO;2-8 CAS PubMed Web of Science® Google Scholar
- 6
French Bone Tumor Study Group.
Age and dose of chemotherapy as major prognostic factors in a trial of adjuvant therapy of osteosarcoma combining two alternative drug combinations and early prophylactic lung irradiation.
Cancer
1988;
61:
1302–1311.
10.1002/1097-0142(19880401)61:7<1304::AID-CNCR2820610705>3.0.CO;2-I Google Scholar
- 7 Rytting M, Pearson P, Raymond A, et al. Osteosarcoma in preadolescent patients. Clin Orthop 2000; 373: 39–50.
- 8 Herson J, Sutow W, Elder K, et al. Adjuvant chemotherapy in nonmetastatic osteosarcoma: A southwest oncology group study. Med Pediatr Oncol 1980; 8: 343–352.
- 9 Provisor A, Ettinger LJ, Nachman J, et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: A report from the Children's Cancer Group. J Clin Oncol 1997; 15: 76–84.
- 10 Hudson M, Jaffe M, Jaffe N, et al. Pediatric osteosarcoma: Therapeutic strategies, results, and pronostic factors derived from a 10-year experience. J Clin Oncol 1990; 8: 1988–1997.
- 11
Kozakewich H,
Perez-Atayde A,
Goorin A, et al.
Osteosarcoma in young children.
Cancer
1991;
67:
638–642.
10.1002/1097-0142(19910201)67:3<638::AID-CNCR2820670319>3.0.CO;2-T CAS PubMed Web of Science® Google Scholar
- 12 Link M, Goorin A, Horowitz M, et al. Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Clin Orthop 1991; 270: 8–14.
- 13 Bacci G, Ferrari S, Mercuri M, et al. Neoadjuvant chemotherapy for extremity osteosarcoma—preliminary results of the Rizzoli's 4th study. Acta Oncologica 1998; 37: 41–48.
- 14
Petrilli AS,
Gentil F,
Epelman S, et al.
Increased survival, limb preservation, and prognostic factors for osteosarcoma.
Cancer
1991;
68:
733–777.
10.1002/1097-0142(19910815)68:4<733::AID-CNCR2820680412>3.0.CO;2-0 CAS PubMed Web of Science® Google Scholar
- 15
Glasser D,
Lane J,
Huvos A, et al.
Survival, prognosis, and therapeutic response in osteogenic sarcoma.
Cancer
1992;
69:
698–708.
10.1002/1097-0142(19920201)69:3<698::AID-CNCR2820690317>3.0.CO;2-G CAS PubMed Web of Science® Google Scholar
- 16 Krailo M, Ertel I, Makley J, et al. A randomized study comparing high-dose methotrexate with moderate-dose methotrexate as components of adjuvant chemotherapy in childhood nonmetastatic osteosarcoma: A report from the children's cancer study group. Med Pediatr Oncol 1987; 15: 69–77.
- 17 Delepine N, Delepine G, Jasmin C, et al. Importance of age and methotrexate dosage: Prognosis in children and young adults with high grade osteosarcoma. Biomed Pharmacother 1988; 42: 257–262.
- 18 Rosen G, Nirenberg A, Caparros B, et al. Osteogenic sarcoma: Eight-percent, 3-year, disease-free survival with combination chemotherapy (T-70). Natl Cancer Inst Monogr 1981; 56: 213–220.
- 19 Wang Y-M, Fujimoto T. Clinical pharmacokinetics of methotrexate in children. Clin Pharmacokinet 1984; 9: 335–348.
- 20 Wang Y-M, Sutow W, Romsdahl M, et al. Age-related pharmacokinetics of high-dose methotrexate in patients with osteosarcoma. Cancer Treat Rep 1979; 63: 405–410.
- 21 Graf N, Winkler K, Betlemovic M. Methotrexate pharmacokinetics and prognosis in osteosarcoma. J Clin Oncol 1994; 12: 1443–1451.
- 22 Bacci G, Picci P, Pignatti G, et al. Neoadjuvant chemotherapy for nonmetastatic osteosarcoma of the extremities. Clin Orthop 1991: 87–98.